{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,13]],"date-time":"2026-04-13T22:24:58Z","timestamp":1776119098292,"version":"3.50.1"},"reference-count":50,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2020,7,1]],"date-time":"2020-07-01T00:00:00Z","timestamp":1593561600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,7,1]],"date-time":"2020-07-01T00:00:00Z","timestamp":1593561600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["jpet.aspetjournals.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["The Journal of Pharmacology and Experimental Therapeutics"],"published-print":{"date-parts":[[2020,7]]},"DOI":"10.1124\/jpet.120.265496","type":"journal-article","created":{"date-parts":[[2020,4,24]],"date-time":"2020-04-24T19:51:06Z","timestamp":1587757866000},"page":"24-37","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":11,"title":["Potential Therapeutic Value of Urotensin II Receptor Antagonist in Chronic Kidney Disease and Associated Comorbidities"],"prefix":"10.1016","volume":"374","author":[{"given":"Marie-Laure","family":"Ozoux","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"V\u00e9ronique","family":"Briand","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Michel","family":"Pelat","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Fabrice","family":"Barbe","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Paul","family":"Schaeffer","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Philippe","family":"Beauverger","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bruno","family":"Poirier","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jean-Michel","family":"Guillon","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Fr\u00e9d\u00e9ric","family":"Petit","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jean-Michel","family":"Altenburger","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jean-Pierre","family":"Bidouard","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Philip","family":"Janiak","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1124\/jpet.120.265496_bib1","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1124\/jpet.301.1.21","article-title":"The angiotensin type 1 receptor antagonist, eprosartan, attenuates the progression of renal disease in spontaneously hypertensive stroke-prone rats with accelerated hypertension","volume":"301","author":"Abrahamsen","year":"2002","journal-title":"J Pharmacol Exp Ther"},{"key":"10.1124\/jpet.120.265496_bib2","unstructured":"Altenburger J-M, Fossey V, Janiak P, Lassalle G, Petit F, Verni\u00e8res J-C (2008) inventors, Sanofi Aventis, assignee. 5,6-Bisaryl-2-pyridine-carboxamide derivatives, preparation and application thereof in therapeutics as urotensin II receptor antagonists. 21\/02\/2008 Patent WO 2008\/020124 A1."},{"key":"10.1124\/jpet.120.265496_bib3","doi-asserted-by":"crossref","first-page":"282","DOI":"10.1038\/45809","article-title":"Human urotensin-II is a potent vasoconstrictor and agonist for the orphan receptor GPR14","volume":"401","author":"Ames","year":"1999","journal-title":"Nature"},{"key":"10.1124\/jpet.120.265496_bib4","doi-asserted-by":"crossref","first-page":"1285","DOI":"10.1056\/NEJMoa041365","article-title":"Relation between renal dysfunction and cardiovascular outcomes after myocardial infarction","volume":"351","author":"Anavekar","year":"2004","journal-title":"N Engl J Med"},{"key":"10.1124\/jpet.120.265496_bib5","doi-asserted-by":"crossref","first-page":"361","DOI":"10.1038\/s41581-018-0001-y","article-title":"CKD in diabetes: diabetic kidney disease versus nondiabetic kidney disease","volume":"14","author":"Anders","year":"2018","journal-title":"Nat Rev Nephrol"},{"key":"10.1124\/jpet.120.265496_bib6","doi-asserted-by":"crossref","first-page":"249790","DOI":"10.1155\/2012\/249790","article-title":"Urotensin-II: more than a mediator for kidney","volume":"2012","author":"Balat","year":"2012","journal-title":"Int J Nephrol"},{"key":"10.1124\/jpet.120.265496_bib7","doi-asserted-by":"crossref","first-page":"948","DOI":"10.1016\/S0022-3565(25)21209-5","article-title":"Chronic carvedilol reduces mortality and renal damage in hypertensive stroke-prone rats","volume":"279","author":"Barone","year":"1996","journal-title":"J Pharmacol Exp Ther"},{"key":"10.1124\/jpet.120.265496_bib8","doi-asserted-by":"crossref","first-page":"274","DOI":"10.1007\/s00210-004-0873-1","article-title":"Urotensin-II: a novel systemic hypertensive factor in the cat","volume":"369","author":"Behm","year":"2004","journal-title":"Naunyn Schmiedebergs Arch Pharmacol"},{"key":"10.1124\/jpet.120.265496_bib9","doi-asserted-by":"crossref","first-page":"374","DOI":"10.1038\/bjp.2008.266","article-title":"Palosuran inhibits binding to primate UT receptors in cell membranes but demonstrates differential activity in intact cells and vascular tissues","volume":"155","author":"Behm","year":"2008","journal-title":"Br J Pharmacol"},{"key":"10.1124\/jpet.120.265496_bib10","doi-asserted-by":"crossref","first-page":"H340","DOI":"10.1152\/ajpheart.01210.2003","article-title":"New insights into the pathological role of TNF-alpha in early cardiac dysfunction and subsequent heart failure after infarction in rats","volume":"287","author":"Berthonneche","year":"2004","journal-title":"Am J Physiol Heart Circ Physiol"},{"key":"10.1124\/jpet.120.265496_bib11","doi-asserted-by":"crossref","first-page":"479","DOI":"10.1007\/s11906-006-0026-7","article-title":"Urotensin-II and cardiovascular diseases","volume":"8","author":"Bousette","year":"2006","journal-title":"Curr Hypertens Rep"},{"key":"10.1124\/jpet.120.265496_bib12","doi-asserted-by":"crossref","first-page":"1200","DOI":"10.1124\/jpet.103.052415","article-title":"Functional and binding characterizations of urotensin II-related peptides in human and rat urotensin II-receptor assay","volume":"306","author":"Brkovic","year":"2003","journal-title":"J Pharmacol Exp Ther"},{"key":"10.1124\/jpet.120.265496_bib13","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1007\/s00210-001-0503-0","article-title":"Effects of human urotensin II in isolated vessels of various species; comparison with other vasoactive agents","volume":"365","author":"Camarda","year":"2002","journal-title":"Naunyn Schmiedebergs Arch Pharmacol"},{"key":"10.1124\/jpet.120.265496_bib14","doi-asserted-by":"crossref","first-page":"76","DOI":"10.3389\/fendo.2017.00076","article-title":"The G protein-coupled receptor UT of the neuropeptide urotensin II displays structural and functional chemokine features","volume":"8","author":"Castel","year":"2017","journal-title":"Front Endocrinol (Lausanne)"},{"key":"10.1124\/jpet.120.265496_bib15","doi-asserted-by":"crossref","first-page":"3099","DOI":"10.1016\/0006-2952(73)90196-2","article-title":"Relationship between the inhibition constant (K1) and the concentration of inhibitor which causes 50 per cent inhibition (I50) of an enzymatic reaction","volume":"22","author":"Cheng","year":"1973","journal-title":"Biochem Pharmacol"},{"key":"10.1124\/jpet.120.265496_bib16","doi-asserted-by":"crossref","first-page":"204","DOI":"10.1124\/jpet.104.068320","article-title":"Pharmacology of the urotensin-II receptor antagonist palosuran (ACT-058362; 1-[2-(4-benzyl-4-hydroxy-piperidin-1-yl)-ethyl]-3-(2-methyl-quinolin-4-yl)-urea sulfate salt): first demonstration of a pathophysiological role of the urotensin System","volume":"311","author":"Clozel","year":"2004","journal-title":"J Pharmacol Exp Ther"},{"key":"10.1124\/jpet.120.265496_bib17","doi-asserted-by":"crossref","first-page":"1115","DOI":"10.1124\/jpet.105.094821","article-title":"The urotensin-II receptor antagonist palosuran improves pancreatic and renal function in diabetic rats","volume":"316","author":"Clozel","year":"2006","journal-title":"J Pharmacol Exp Ther"},{"key":"10.1124\/jpet.120.265496_bib18","doi-asserted-by":"crossref","first-page":"226","DOI":"10.1002\/(SICI)1097-010X(19960601\/15)275:2\/3<226::AID-JEZ14>3.0.CO;2-H","article-title":"Distribution and molecular forms of urotensin II and its role in cardiovascular regulation in vertebrates","volume":"275","author":"Conlon","year":"1996","journal-title":"J Exp Zool"},{"key":"10.1124\/jpet.120.265496_bib19","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1016\/S0014-5793(99)01003-0","article-title":"Cloning, sequence analysis and tissue distribution of the mouse and rat urotensin II precursors","volume":"457","author":"Coulouarn","year":"1999","journal-title":"FEBS Lett"},{"key":"10.1124\/jpet.120.265496_bib20","doi-asserted-by":"crossref","first-page":"1262","DOI":"10.1038\/sj.bjp.0703690","article-title":"Differential vasoconstrictor activity of human urotensin-II in vascular tissue isolated from the rat, mouse, dog, pig, marmoset and cynomolgus monkey","volume":"131","author":"Douglas","year":"2000","journal-title":"Br J Pharmacol"},{"key":"10.1124\/jpet.120.265496_bib21","doi-asserted-by":"crossref","first-page":"1990","DOI":"10.1016\/S0140-6736(02)08831-1","article-title":"Congestive heart failure and expression of myocardial urotensin II","volume":"359","author":"Douglas","year":"2002","journal-title":"Lancet"},{"key":"10.1124\/jpet.120.265496_bib22","doi-asserted-by":"crossref","first-page":"9583","DOI":"10.1038\/s41598-019-46074-2","article-title":"Intelligent diagnostic prediction and classification system for chronic kidney disease","volume":"9","author":"Elhoseny","year":"2019","journal-title":"Sci Rep"},{"key":"10.1124\/jpet.120.265496_bib23","doi-asserted-by":"crossref","first-page":"421","DOI":"10.1113\/EP087366","article-title":"Urotensin II in the development and progression of chronic kidney disease following \u215a nephrectomy in the rat","volume":"104","author":"Eyre","year":"2019","journal-title":"Exp Physiol"},{"key":"10.1124\/jpet.120.265496_bib24","doi-asserted-by":"crossref","first-page":"1625","DOI":"10.1038\/sj.bjp.0704051","article-title":"Depressor and regionally-selective vasodilator effects of human and rat urotensin II in conscious rats","volume":"132","author":"Gardiner","year":"2001","journal-title":"Br J Pharmacol"},{"key":"10.1124\/jpet.120.265496_bib25","doi-asserted-by":"crossref","first-page":"653","DOI":"10.1111\/j.1751-7176.2010.00336.x","article-title":"Raised plasma urotensin II in type 2 diabetes patients is associated with the metabolic syndrome phenotype","volume":"12","author":"Gruson","year":"2010","journal-title":"J Clin Hypertens (Greenwich)"},{"key":"10.1124\/jpet.120.265496_bib26","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1007\/BF00656997","article-title":"Improved patch-clamp techniques for high-resolution current recording from cells and cell-free membrane patches","volume":"391","author":"Hamill","year":"1981","journal-title":"Pflugers Arch"},{"key":"10.1124\/jpet.120.265496_bib27","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1007\/978-1-59745-352-3_4","article-title":"Small animal models of kidney disease: a review","volume":"466","author":"Hewitson","year":"2009","journal-title":"Methods Mol Biol"},{"key":"10.1124\/jpet.120.265496_bib28","doi-asserted-by":"crossref","first-page":"826","DOI":"10.1016\/S0272-6386(04)01130-8","article-title":"Increased expression of urotensin II and urotensin II receptor in human diabetic nephropathy","volume":"44","author":"Langham","year":"2004","journal-title":"Am J Kidney Dis"},{"key":"10.1124\/jpet.120.265496_bib50","doi-asserted-by":"crossref","first-page":"1753","DOI":"10.1038\/s41591-019-0627-8","article-title":"Glomerular filtration rate by differing measures, albuminuria and prediction of vascular disease, mortality and end-stage kidney disease","volume":"25","author":"Lees","year":"2019","journal-title":"Nature Medicine"},{"key":"10.1124\/jpet.120.265496_bib29","doi-asserted-by":"crossref","first-page":"1888","DOI":"10.1016\/S0140-6736(17)30788-2","article-title":"Global kidney health 2017 and beyond: a roadmap for closing gaps in care, research, and policy","volume":"390","author":"Levin","year":"2017","journal-title":"Lancet"},{"key":"10.1124\/jpet.120.265496_bib30","first-page":"CD012466","article-title":"Pharmacological interventions for heart failure in people with chronic kidney disease","volume":"2","author":"Lunney","year":"2020","journal-title":"Cochrane Database Syst Rev"},{"key":"10.1124\/jpet.120.265496_bib31","doi-asserted-by":"crossref","first-page":"414","DOI":"10.2471\/BLT.17.206441","article-title":"The global burden of kidney disease and the sustainable development goals","volume":"96","author":"Luyckx","year":"2018","journal-title":"Bull World Health Organ"},{"key":"10.1124\/jpet.120.265496_bib32","doi-asserted-by":"crossref","first-page":"2028","DOI":"10.2741\/3361","article-title":"PAI-1 and kidney fibrosis","volume":"14","author":"Ma","year":"2009","journal-title":"Front Biosci"},{"key":"10.1124\/jpet.120.265496_bib33","doi-asserted-by":"crossref","first-page":"711","DOI":"10.1016\/j.peptides.2007.12.015","article-title":"Urotensin II and urotensin II-related peptide activate somatostatin receptor subtypes 2 and 5","volume":"29","author":"Malagon","year":"2008","journal-title":"Peptides"},{"key":"10.1124\/jpet.120.265496_bib34","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1016\/j.pharmthera.2013.10.007","article-title":"Small and large animal models in cardiac contraction research: advantages and disadvantages","volume":"141","author":"Milani-Nejad","year":"2014","journal-title":"Pharmacol Ther"},{"key":"10.1124\/jpet.120.265496_bib35","doi-asserted-by":"crossref","first-page":"725","DOI":"10.1016\/j.tips.2019.08.005","article-title":"Towards targeting the urotensinergic system: overview and challenges","volume":"40","author":"Nassour","year":"2019","journal-title":"Trends Pharmacol Sci"},{"key":"10.1124\/jpet.120.265496_bib36","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1152\/physrev.2000.80.1.135","article-title":"Genetic analysis of inherited hypertension in the rat","volume":"80","author":"Rapp","year":"2000","journal-title":"Physiol Rev"},{"issue":"Suppl 1","key":"10.1124\/jpet.120.265496_bib37","doi-asserted-by":"crossref","first-page":"S48","DOI":"10.1681\/ASN.2004110957","article-title":"Prevention and treatment of diabetic nephropathy: the program for irbesartan mortality and morbidity evaluation","volume":"16","author":"Ravera","year":"2005","journal-title":"J Am Soc Nephrol"},{"key":"10.1124\/jpet.120.265496_bib38","doi-asserted-by":"crossref","first-page":"545","DOI":"10.1016\/S0140-6736(02)09709-X","article-title":"Plasma urotensin II in heart failure","volume":"360","author":"Richards","year":"2002","journal-title":"Lancet"},{"key":"10.1124\/jpet.120.265496_bib39","doi-asserted-by":"crossref","first-page":"675","DOI":"10.1038\/hr.2012.77","article-title":"Mapping genetic determinants of kidney damage in rat models","volume":"35","author":"Schulz","year":"2012","journal-title":"Hypertens Res"},{"key":"10.1124\/jpet.120.265496_bib40","doi-asserted-by":"crossref","first-page":"398","DOI":"10.1177\/000331976001100505","article-title":"Simple techniques for the surgical occlusion of coronary vessels in the rat","volume":"11","author":"Selye","year":"1960","journal-title":"Angiology"},{"key":"10.1124\/jpet.120.265496_bib41","doi-asserted-by":"crossref","first-page":"502","DOI":"10.1111\/j.1365-2125.2009.03480.x","article-title":"Effect of the urotensin-II receptor antagonist palosuran on secretion of and sensitivity to insulin in patients with Type 2 diabetes mellitus","volume":"68","author":"Sidharta","year":"2009","journal-title":"Br J Clin Pharmacol"},{"key":"10.1124\/jpet.120.265496_bib42","doi-asserted-by":"crossref","first-page":"4664","DOI":"10.1210\/en.2006-0274","article-title":"Antidiabetic activity of a highly potent and selective nonpeptide somatostatin receptor subtype-2 agonist","volume":"147","author":"Strowski","year":"2006","journal-title":"Endocrinology"},{"key":"10.1124\/jpet.120.265496_bib43","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1042\/cs1040001","article-title":"Increased plasma urotensin II levels in patients with diabetes mellitus","volume":"104","author":"Totsune","year":"2003","journal-title":"Clin Sci (Lond)"},{"key":"10.1124\/jpet.120.265496_bib44","doi-asserted-by":"crossref","first-page":"38","DOI":"10.3389\/fphar.2011.00038","article-title":"Potential clinical implications of the urotensin II receptor antagonists","volume":"2","author":"Tsoukas","year":"2011","journal-title":"Front Pharmacol"},{"key":"10.1124\/jpet.120.265496_bib45","doi-asserted-by":"crossref","first-page":"214","DOI":"10.1124\/pr.114.009480","article-title":"International Union of Basic and Clinical Pharmacology. XCII. Urotensin II, urotensin II-related peptide, and their receptor: from structure to function","volume":"67","author":"Vaudry","year":"2015","journal-title":"Pharmacol Rev"},{"key":"10.1124\/jpet.120.265496_bib46","doi-asserted-by":"crossref","first-page":"1206","DOI":"10.1161\/HYPERTENSIONAHA.109.149559","article-title":"Effect of the urotensin receptor antagonist palosuran in hypertensive patients with type 2 diabetic nephropathy","volume":"55","author":"Vogt","year":"2010","journal-title":"Hypertension"},{"key":"10.1124\/jpet.120.265496_bib47","doi-asserted-by":"crossref","first-page":"1155","DOI":"10.1007\/s00125-013-2837-9","article-title":"Urotensin II receptor antagonism confers vasoprotective effects in diabetes associated atherosclerosis: studies in humans and in a mouse model of diabetes","volume":"56","author":"Watson","year":"2013","journal-title":"Diabetologia"},{"key":"10.1124\/jpet.120.265496_bib48","doi-asserted-by":"crossref","first-page":"737","DOI":"10.1097\/00005344-200111000-00010","article-title":"Drug block of I(kr): model systems and relevance to human arrhythmias","volume":"38","author":"Yang","year":"2001","journal-title":"J Cardiovasc Pharmacol"},{"key":"10.1124\/jpet.120.265496_bib49","doi-asserted-by":"crossref","first-page":"H830","DOI":"10.1152\/ajpheart.00406.2003","article-title":"Urotensin II causes fatal circulatory collapse in anesthesized monkeys in vivo: a \u201cvasoconstrictor\u201d with a unique hemodynamic profile","volume":"286","author":"Zhu","year":"2004","journal-title":"Am J Physiol Heart Circ Physiol"}],"container-title":["The Journal of Pharmacology and Experimental Therapeutics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0022356524257888?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0022356524257888?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1124\/jpet.120.265496","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,2,19]],"date-time":"2025-02-19T13:54:42Z","timestamp":1739973282000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0022356524257888"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,7]]},"references-count":50,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2020,7]]}},"alternative-id":["S0022356524257888"],"URL":"https:\/\/doi.org\/10.1124\/jpet.120.265496","relation":{},"ISSN":["0022-3565"],"issn-type":[{"value":"0022-3565","type":"print"}],"subject":[],"published":{"date-parts":[[2020,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Potential Therapeutic Value of Urotensin II Receptor Antagonist in Chronic Kidney Disease and Associated Comorbidities","name":"articletitle","label":"Article Title"},{"value":"The Journal of Pharmacology and Experimental Therapeutics","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1124\/jpet.120.265496","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2020 by The Author(s)","name":"copyright","label":"Copyright"}]}}